- ResApp Health (RAP) has completed recruitment for its COVID-19 study in India ahead of schedule
- The company’s trial enrolled 337 patients in India, including over 200 COVID-19 positive cases, with inpatients providing cough sound samples during their hospital stay
- ResApp says the data collected will be used to develop and train machine learning algorithms to identify COVID-19 from cough sounds recorded on a smartphone
- Meanwhile, ResApp’s has enrolled its first patient for its US based study, with recruitment expected to be complete by mid-December
- ResApp Health was up 1.82 per cent, trading at 5.6 cents at 11:45 am AEDT
ResApp Health (RAP) has completed recruitment for its COVID-19 study in India.
ResApp’s study enrolled 337 patients across two study arms in India, which included over 200 COVID-19 positive cases.
Both positive and negative cases were confirmed using polymerase chain reaction (PCR) pathology testing.
For the trial, both outpatients and inpatients were recruited, with inpatients additionally providing cough sound samples multiple times during their hospital stay to help the team understand more about the progression of the disease.
ResApp said it will use the data collected in these studies to develop and train machine learning algorithms to identify COVID-19 from cough sounds recorded on a smartphone.
CEO and Managing Director, Dr Tony Keating, said the company is pleased to report the recruitment in India was complete ahead of schedule.
“This is an important milestone in collecting a high-quality dataset to perform the necessary development work to build, train and test machine learning algorithms capable of identifying COVID-19 from cough sounds,” Dr Keating said.
“Experts agree that screening and management of COVID-19 will be an ongoing requirement for many years and ResApp is focused on the development of instant smartphone based applications to fulfill these global needs.”
Meanwhile, ResApp’s US-based study has been expanded to allow recruitment from in-person COVID-19 testing clinics, on top of its existing at-home recruitment.
The first patient has been enrolled in the US study, with recruitment expected to be complete by mid-December.
ResApp Health was up 1.82 per cent, trading at 5.6 cents at 11:45 am AEDT.